XML 50 R18.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC | 9 Months Ended
--- | ---
Sep. 30, 2014
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC [Abstract] |
Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC |
13. | Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC
On July 30, 2013, we entered into a Sale and Exclusive License/Supply Agreement with Bimini Technologies LLC (“Bimini”), pursuant to which we sold to Bimini substantially all of the assets (other than certain retained rights and licenses) of our Puregraft® product line, a series of standalone fat transplantation products that were developed to improve the predictability of outcomes for autologous fat grafting and aesthetic body contouring. The aggregate value of the consideration paid by Bimini at the execution of the agreement was $5.0 million. In connection with the sale, Bimini granted to the Company an exclusive, perpetual, royalty bearing license to market and sell the Puregraft products for use in combination with adipose derived regenerative cells, and non-exclusive rights for use in connection with the Company’s licensed cell and tissue banks. The Company will supply Puregraft products to Bimini on an interim basis until the Company transfers the manufacturing of the Puregraft products to Bimini. After the transfer, Bimini will supply the Puregraft products to the Company. Pursuant to the sale agreement, the Company has also granted to Bimini the global, exclusive, perpetual, irrevocable royalty bearing license to purchase from Cytori, use and sell the Celution® System products for Alopecia (hair loss). Cytori will supply Celution devices and consumable sets to Bimini, and Bimini will be responsible for all costs associated with commercial development in the Alopecia market. The agreement includes certain obligations to be performed by the Company on the behalf of Bimini, which includes transferring the manufacturing of Puregraft products to an agreed upon third party on or before December 31, 2014 and training. The Company recorded a gain on the Puregraft divestiture of $4.5 million in 2013, and has a remaining obligation of approximately $158,000 in future transfer and training obligations, as of September 30, 2014. Bimini is obligated to make certain additional milestone payments to the Company (in an aggregate amount of up to $10.0 million), contingent upon the achievement of certain milestones relating to Bimini’s gross profits from sales of the Puregraft products.

X
- Definition The entire disclosure for the reporting entity's sale and exclusive license/supply agreement. + References No definition available. + Details
Name: | cytx_SaleAndExclusiveLicenseSupplyAgreementTextBlock
Namespace Prefix: | cytx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | cytx_SaleAndExclusiveLicenseSupplyAgreementWithBiminiTechnologiesLlcAbstract
Namespace Prefix: | cytx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration